Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?
This review explores the potential of targeting mast cells, particularly in early phases, for treating multiple sclerosis and endometriosis by leveraging a proposed nerve-mast cell-myofibroblast axis involved in fibrogenic inflammation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Full text
1,254 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-05-11T03:53:04.819938+00:00